Print
Save
Email this link

Share Link

Copy this link, or click below to email it to a friend
Email this link
or copy the link directly:

https://ec.bioscientifica.com/search?access=user&fulltext=HPA+axis&pageSize=10&sort=relevance&t=EC-Hormones-and-Cancer
The link was not copied. Your current browser may not support copying via this button.

Link copied successfully

Search Results

You are looking at 1 - 1 of 1 items for :

null x

Hormones and Cancer x

Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer

Ruth Percik

Ruth Percik Institute of Endocrinology, Diabetes and Metabolism, Sheba Medical Centre, Ramat Gan, Israel

Search for other papers by Ruth Percik in
Google Scholar
PubMed

Sherwin Criseno

Sherwin Criseno Department of Endocrinology, University Hospital Birmingham, Birmingham, UK

Search for other papers by Sherwin Criseno in
Google Scholar
PubMed

Safwaan Adam

Safwaan Adam Department of Endocrinology, The Christie NHS Foundation Trust, Manchester, UK

Search for other papers by Safwaan Adam in
Google Scholar
PubMed

Kate Young

Kate Young Royal Marsden Hospital, London, UK

Search for other papers by Kate Young in
Google Scholar
PubMed

, and

Daniel L Morganstein

Daniel L Morganstein Department of Endocrinology, Chelsea and Westminster Hospital, London, UK
Royal Marsden Hospital, London, UK

Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed

. Hypothalamic–pituitary–adrenal (HPA) axis Hypophysitis and hypopituitarism Pituitary abnormalities are reported in between 1.8 and 18.3% of patients treated with ipilimumab-based regimens ( 17 ), usually resulting in panhypopituitarism, associated with